{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d196fab2-faea-4024-913d-3b19916237a0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n",
      "    {\n",
      "        \"question\": \"What defines triple negative breast cancer (TNBC) at the immunohistochemical level?\",\n",
      "        \"reference\": \"Lack of expression (< 1%) of ER, PgR, and HER2.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of all breast cancers does TNBC account for?\",\n",
      "        \"reference\": \"Approximately 10-20%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What patient population is most commonly affected by TNBC?\",\n",
      "        \"reference\": \"Young, premenopausal women.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What kind of genetic alterations are associated with TNBC?\",\n",
      "        \"reference\": \"BRCA 1/2 mutations.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How would you describe the biological behavior of TNBC?\",\n",
      "        \"reference\": \"Aggressive, higher grade, often lymph node involvement, inclination to metastasize.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What has been the traditional treatment for early TNBC?\",\n",
      "        \"reference\": \"Surgery and adjuvant chemotherapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What has conventional cytotoxic chemotherapy represented in early TNBC?\",\n",
      "        \"reference\": \"The backbone of systemic treatment.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the purpose of neoadjuvant treatment?\",\n",
      "        \"reference\": \"To reduce tumor size.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What two types of inhibitors have shown survival benefits in recent TNBC studies?\",\n",
      "        \"reference\": \"Immunotherapy and PARP inhibitors.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What could combinations of immune checkpoint inhibitors (ICIs) emerge as in the management of TNBC patients?\",\n",
      "        \"reference\": \"A successful therapeutic approach.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What type of comprehension would amplify the potential for developing targeted immunotherapy in TNBC?\",\n",
      "        \"reference\": \"Comprehension of tumor subtypes, TME, and molecular, genetic, and immune aspects.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What specific role of immunotherapy is this review aiming to investigate?\",\n",
      "        \"reference\": \"Its role in early-stage TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What prognostic value are the authors aiming to investigate?\",\n",
      "        \"reference\": \"Pathologic complete response (pCR).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What makes TNBC a promising candidate for immunotherapy?\",\n",
      "        \"reference\": \"Its high immunogenic potential.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is TNBC immunogenicity related to?\",\n",
      "        \"reference\": \"Intrinsic tumor cell signatures and tumoral surrounding microenvironment features.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What emerging technologies have improved the knowledge of the molecular and genetic background of TNBC?\",\n",
      "        \"reference\": \"Next-generation sequencing (NGS).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What did the first classification divide TNBC into?\",\n",
      "        \"reference\": \"Basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), M stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How many TNBC tumors were analyzed to shape a four-type classification of TNBC?\",\n",
      "        \"reference\": \"198.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the four specific TNBC subtypes identified after revision?\",\n",
      "        \"reference\": \"BL1, BL2, M, and LAR.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What were IM and MSL subtypes omitted?\",\n",
      "        \"reference\": \"Because of the dependence of these two subtypes on the TME features.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How can TNBC be classified in addition to subtypes?\",\n",
      "        \"reference\": \"Into three microenvironment phenotypes or clusters.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What characterizes Cluster 1?\",\n",
      "        \"reference\": \"\\\"Immune-desert\\\" with poor immune cell permeation, due to a high presence of MYC amplifications.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What pathway is hyper-activated in Cluster 2?\",\n",
      "        \"reference\": \"Phosphatidylinositide 3-kinase/protein kinase B (PI3K-AKT) pathway.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are Clusters 1 and 2 referred to?\",\n",
      "        \"reference\": \"\\\"Cold tumors.\\\"\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of TNBCs does Cluster 3 represent?\",\n",
      "        \"reference\": \"About 30%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is Cluster 3 characterized by?\",\n",
      "        \"reference\": \"An abundant adaptive and innate immune cells infiltration and with a high expression of immune checkpoint molecules.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is another name for Cluster 3?\",\n",
      "        \"reference\": \"\\\"Hot tumor.\\\"\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What could the potential \\\"hot\\\" conversion of \\\"cold\\\" tumors improve?\",\n",
      "        \"reference\": \"The efficacy of cancer immunotherapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How can local IM therapies express a synergistic effect with immunotherapy?\",\n",
      "        \"reference\": \"By acting on components of the TME and immune system function, elevating the expression of tumor antigens and increasing the recruitment of activated immune cells in the TME.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is one way local IM therapies may synergize with immunotherapy?\",\n",
      "        \"reference\": \"Elevating the expression of tumor antigens.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of breast malignancies does TNBC account for?\",\n",
      "        \"reference\": \"TNBC accounts for approximately 15-20% of breast malignancies.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What treatment has been the mainstay for early-stage TNBC patients?\",\n",
      "        \"reference\": \"Anthracycline- and taxane-based chemotherapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"Which PD-1 inhibitor has been approved for patients with advanced PD-L1-positive and early high-risk TNBC?\",\n",
      "        \"reference\": \"Pembrolizumab.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are PARPi, PD-(L)1 inhibitors, and ADCs approved for?\",\n",
      "        \"reference\": \"The treatment of TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the three stages of \\\"cancer immunoediting\\\"?\",\n",
      "        \"reference\": \"Elimination, equilibrium, and escape.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What do APCs mainly include?\",\n",
      "        \"reference\": \"Dendritic cells (DCs).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the single-agent effectiveness of PD-(L)1 inhibitors in patients with PD-L1-positive metastatic TNBC (mTNBC)?\",\n",
      "        \"reference\": \"Approximately 20%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What characteristics of TNBC, compared to other subtypes, make it more likely to benefit from immunotherapy?\",\n",
      "        \"reference\": \"Higher PD-L1 expression and tumor-infiltrating lymphocytes (TILs).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"Besides T cells, what other immune cells are essential for tumor cell elimination?\",\n",
      "        \"reference\": \"B cells and innate immune cells, such as natural killer (NK) cells.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the main challenge in TNBC treatment due to the absence of specific receptors?\",\n",
      "        \"reference\": \"TNBC cannot benefit from endocrine or anti-HER-2 therapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What systemic treatment was historically the only option for TNBC?\",\n",
      "        \"reference\": \"Chemotherapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What launched the era of immunotherapy in TNBC?\",\n",
      "        \"reference\": \"The successful application of immune checkpoint inhibitors (ICIs).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the primary reason for the poor prognosis of TNBC?\",\n",
      "        \"reference\": \"The lack of effective treatment options.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What needs to be considered when combining multiple drugs for TNBC treatment?\",\n",
      "        \"reference\": \"The side effects associated with the combination.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the significance of genomic advances in TNBC?\",\n",
      "        \"reference\": \"They reveal a high degree of heterogeneity and set the stage for targeted therapies.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the definition of mTNBC?\",\n",
      "        \"reference\": \"metastatic TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the purpose of the review described in the abstract?\",\n",
      "        \"reference\": \"To analyze immunotherapy strategies, summarize clinical trials, review results, and shed light on future developments in TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are tumor cells releasing, which are captured by antigen-presenting cells?\",\n",
      "        \"reference\": \"Specific antigens.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the expected impact of immune combination therapy in TNBC?\",\n",
      "        \"reference\": \"To further enhance the efficacy and expand the beneficiary population of patients.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How soon do most TNBC patients develop recurrence and metastasis?\",\n",
      "        \"reference\": \"Within 3 years.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the first step in the cascade of events for tumor cell elimination?\",\n",
      "        \"reference\": \"Tumor cells release specific antigens.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the main role of DCs in the process of tumor cell elimination?\",\n",
      "        \"reference\": \"To present antigenic signals to T cells.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What do T cells do after activation in the process of tumor cell elimination?\",\n",
      "        \"reference\": \"They transport and infiltrate tumor tissues.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are being analyzed in the review in terms of the poor efficacy of PD-(L)1 inhibitors monotherapy?\",\n",
      "        \"reference\": \"Tumor immune escape mechanisms and tumor immune microenvironment (TIME) characteristics of TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What needs to be selected to identify the target population for effective TNBC treatments?\",\n",
      "        \"reference\": \"Effective biomarkers.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the three main hormone receptors not expressed in TNBC?\",\n",
      "        \"reference\": \"Estrogen receptors, progesterone receptors and HER-2.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the possible negative effects linked to immunotherapy in TNBC?\",\n",
      "        \"reference\": \"Possible adverse events.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"In what condition is pembrolizumab approved to treat TNBC?\",\n",
      "        \"reference\": \"advanced PD-L1-positive and early high-risk disease.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What cascade event happens right after tumor cells release specific antigens?\",\n",
      "        \"reference\": \"Antigens are captured and processed by APCs.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How can the interaction between tumor cells and the TIME be described?\",\n",
      "        \"reference\": \"Cancer immunoediting.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of all breast cancer cases does TNBC account for?\",\n",
      "        \"reference\": \"10-15%\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What receptors are lacking in TNBC?\",\n",
      "        \"reference\": \"Estrogen and progesterone receptors.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"Is TNBC sensitive to chemotherapy?\",\n",
      "        \"reference\": \"Yes.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are some subgroups of TNBC that have seen recent advances with novel agents?\",\n",
      "        \"reference\": \"PD-L1+ tumors and germline Brca-mutated tumors.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the standard of care for TNBC?\",\n",
      "        \"reference\": \"Chemotherapy.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the criteria to classify breast cancer subtypes?\",\n",
      "        \"reference\": \"Molecular profile based on biomarkers like ER?, PR, and HER2.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How is TNBC characterized according to ASCO/CAP guidelines?\",\n",
      "        \"reference\": \"?1% ER/PR expression by IHC, and HER2 expression of 0-1+ by IHC or 2+ by IHC and FISH negative.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are the four distinct transcriptional subtypes of TNBC?\",\n",
      "        \"reference\": \"BL1, BL2, M, and LAR.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of newly diagnosed breast cancers does TNBC represent?\",\n",
      "        \"reference\": \"15-20%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the median overall survival for TNBC with current therapies?\",\n",
      "        \"reference\": \"10.2 months.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What does the current SOC for newly diagnosed early TNBC consist of?\",\n",
      "        \"reference\": \"Neoadjuvant chemotherapy followed by surgery.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What are some available therapies for patients with advanced TNBC?\",\n",
      "        \"reference\": \"Capecitabine, gemcitabine, eribulin, and platinums.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How does TNBC compare to other breast cancer subtypes in terms of immunogenicity?\",\n",
      "        \"reference\": \"TNBC is more immunogenic.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the relationship between PD-L1 expression and TNBC?\",\n",
      "        \"reference\": \"TNBC displays a high level of PD-L1 expression.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What immunotherapy drug was approved by the FDA in combination with nab-paclitaxel for TNBC?\",\n",
      "        \"reference\": \"Atezolizumab.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"For whom was atezolizumab approved as a first-line therapy?\",\n",
      "        \"reference\": \"Patients with PD-L1+, unresectable, locally advanced or metastatic TNBC.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of enrolled patients showed PD -L1-positive expression in the IMpassion130 trial?\",\n",
      "        \"reference\": \"41%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What immunotherapy was approved in 2017 as a histology agnostic immunotherapy in all microsatellite instability -high (MSI -H) and/or mismatch repair deficient (dMMR) tumors?\",\n",
      "        \"reference\": \"Pembrolizumab.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"How common is MSI-H in breast cancer?\",\n",
      "        \"reference\": \"Rare, less than 2%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the relationship between BRCA1/2-deficient tumors and PARP inhibitors?\",\n",
      "        \"reference\": \"They exhibit synthetic lethality with PARP inhibitors.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What PARP inhibitors were approved by the FDA for advanced-stage HER2-negative breast cancer in individuals with BRCA1 or BRCA2 mutations?\",\n",
      "        \"reference\": \"Olaparib and talazoparib.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What percentage of breast cancer patients carry a gBRCAm?\",\n",
      "        \"reference\": \"Approximately 5%.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What was olaparib compared to in the OlympiAD Phase III trial?\",\n",
      "        \"reference\": \"Physician's choice of chemotherapy (capecitabine, vinorelbine or eribulin).\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What was the effect of olaparib on median PFS compared to the control group in the OlympiAD trial?\",\n",
      "        \"reference\": \"A 42% increase in median PFS.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What was talazoparib compared to in the EMBRACA Phase III trial?\",\n",
      "        \"reference\": \"Gemcitabine or the same physician's choice of standard therapy as the OlympiAD trial.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What was the effect of talazoparib on median PFS compared to the control group in the EMBRACA trial?\",\n",
      "        \"reference\": \"A 46% increase in median PFS.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What grade 3-4 AEs were primarily associated with talazoparib?\",\n",
      "        \"reference\": \"Anemia.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What agents have been explored in clinical studies to improve therapeutic benefit in TNBC treatment?\",\n",
      "        \"reference\": \"Immuno- and targeted therapies.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the median progression-free survival (PFS) with chemotherapy for TNBC?\",\n",
      "        \"reference\": \"1.7 to 3.7 months.\"\n",
      "    },\n",
      "    {\n",
      "        \"question\": \"What is the median OS from the onset of metastasis for TNBC?\",\n",
      "        \"reference\": \"10 to 13 months.\"\n",
      "    }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import json\n",
    "\n",
    "# Load the Excel file\n",
    "file_path = \"qca_dataset_specific_v2(Sheet1).csv\"  # Update with your actual file path\n",
    "df = pd.read_csv(file_path)\n",
    "\n",
    "# Convert to JSON format\n",
    "json_data = df.rename(columns={'question': 'question', 'answer': 'reference'}).to_dict(orient='records')\n",
    "\n",
    "# Save JSON to a file or print\n",
    "json_output_path = \"output.json\"\n",
    "with open(json_output_path, \"w\", encoding=\"utf-8\") as json_file:\n",
    "    json.dump(json_data, json_file, indent=4, ensure_ascii=False)\n",
    "\n",
    "# Print the JSON\n",
    "print(json.dumps(json_data, indent=4, ensure_ascii=False))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1dba4793-a2d0-41cf-8f0e-b3960834b3b4",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
